XML 34 R2.htm IDEA: XBRL DOCUMENT
v3.23.1

Pay vs Performance Disclosure | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) $ / shares | Dec. 31, 2020 USD ($) $ / shares | Mar. 17, 2022 $ / shares | Mar. 12, 2021 $ / shares | Mar. 17, 2020 $ / shares | Dec. 31, 2019 $ / shares | Mar. 14, 2019 $ / shares | Oct. 01, 2018 $ / shares
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Pay vs Performance [Table Text Block] | Pay Versus Performance As required by Item 402(v) of Regulation S-K, we are providing the following information regarding the relationship between executive compensation and our financial performance for each of the last three completed calendar years. In determining the “compensation actually paid” to our NEOs, we are required to make various adjustments to amounts that have been reported in the Summary Compensation Table in previous years since the required valuation methods for this section differ from those required in the Summary Compensation Table. The table below summarizes compensation values both previously reported in our Summary Compensation Table and the adjusted values required in this section for calendar years 2020, 2021 and 2022.
​ | ​ | Year | ​ | ​ | ​ | Summary Compensation Table (SCT) Total for PEO ($)(1) | ​ | ​ | ​ | Compensation Actually Paid to PEO ($)(1)(3) | ​ | ​ | ​ | Average SCT Total for Non-PEO NEOs ($)(2) | ​ | ​ | ​ | Average Compensation Actually Paid to Non-PEO NEOs ($)(2)(3) | ​ | ​ | ​ | Value of Initial Fixed $100 Investment based on: | ​ | ​ | ​ | Net Income ($ thousands) | ​ | ​ | ​ | Adjusted Operating Income ($ thousands) | ​ | ​
​ | Company TSR(4) | ​ | ​ | ​ | Peer Group TSR(4) | ​ | ​
​ | ​ | 2022 | ​ | ​ | ​ | ​ | ​ | 5,914,884 | ​ | ​ | ​ | ​ | ​ | ​ | 894,752 | ​ | ​ | ​ | ​ | ​ | ​ | 1,769,683 | ​ | ​ | ​ | ​ | ​ | ​ | 409,560 | ​ | ​ | ​ | ​ | ​ | ​ | 126.48 | ​ | ​ | ​ | ​ | ​ | ​ | 36.09 | ​ | ​ | ​ | ​ | ​ | ​ | 166,942 | ​ | ​ | ​ | ​ | ​ | ​ | 116.6 | ​ | ​ | ​
​ | ​ | 2021 | ​ | ​ | ​ | ​ | ​ | 4,526,501 | ​ | ​ | ​ | ​ | ​ | ​ | 13,102,240 | ​ | ​ | ​ | ​ | ​ | ​ | 1,514,852 | ​ | ​ | ​ | ​ | ​ | ​ | 2,755,988 | ​ | ​ | ​ | ​ | ​ | ​ | 193.81 | ​ | ​ | ​ | ​ | ​ | ​ | 81.82 | ​ | ​ | ​ | ​ | ​ | ​ | 26,038 | ​ | ​ | ​ | ​ | ​ | ​ | 104.3 | ​ | ​ | ​
​ | ​ | 2020 | ​ | ​ | ​ | ​ | ​ | 2,610,509 | ​ | ​ | ​ | ​ | ​ | ​ | 5,331,974 | ​ | ​ | ​ | ​ | ​ | ​ | 1,138,308 | ​ | ​ | ​ | ​ | ​ | ​ | 1,483,327 | ​ | ​ | ​ | ​ | ​ | ​ | 118.18 | ​ | ​ | ​ | ​ | ​ | ​ | 132.76 | ​ | ​ | ​ | ​ | ​ | ​ | (8,391) | ​ | ​ | ​ | ​ | ​ | ​ | 66.9 | ​ | ​ | ​
​ (1) The PEO (principal executive officer) for each year presented was identified as Dr. Miller, the Company’s CEO. ​ (2) The Non-PEO NEOs for each year presented were identified as Mr. Kiernan, Drs. Devasahayam and Porshnev, and Ms. Wilkerson. ​ (3) A reconciliation of Total Compensation per the Summary Compensation Table to Compensation Actually Paid is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | 2022 | ​ | ​ | ​ | 2021 | ​ | ​ | ​ | 2020 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​
​ | ​ | Total Compensation from SCT | ​ | ​ | ​ | ​ | ​ | 5,914,884 | ​ | ​ | ​ | ​ | ​ | ​ | 1,769,683 | ​ | ​ | ​ | ​ | ​ | ​ | 4,526,501 | ​ | ​ | ​ | ​ | ​ | ​ | 1,514,852 | ​ | ​ | ​ | ​ | ​ | ​ | 2,610,509 | ​ | ​ | ​ | ​ | ​ | ​ | 1,138,308 | ​ | ​ | ​
​ | ​ | Deduct: Amounts Reported Under “Stock Awards” and “Option Awards” columns in SCT | ​ | ​ | ​ | ​ | ​ | (4,741,020) | ​ | ​ | ​ | ​ | ​ | ​ | (1,135,870) | ​ | ​ | ​ | ​ | ​ | ​ | (3,122,580) | ​ | ​ | ​ | ​ | ​ | ​ | (813,172) | ​ | ​ | ​ | ​ | ​ | ​ | (1,121,618) | ​ | ​ | ​ | ​ | ​ | ​ | (460,253) | ​ | ​ | ​
​ | ​ | Add: Year-end value of equity awards granted in covered year that were outstanding and unvested as of the end of the covered fiscal year﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | 2,517,420 | ​ | ​ | ​ | ​ | ​ | ​ | 603,132 | ​ | ​ | ​ | ​ | ​ | ​ | 4,362,540 | ​ | ​ | ​ | ​ | ​ | ​ | 1,136,078 | ​ | ​ | ​ | ​ | ​ | ​ | 2,140,579 | ​ | ​ | ​ | ​ | ​ | ​ | 780,839 | ​ | ​ | ​
​ | ​ | Add: The amount of change in fair values as of year-end (from end of the prior year) of awards granted in prior years and outstanding at year-end﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | (2,779,460) | ​ | ​ | ​ | ​ | ​ | ​ | (737,886) | ​ | ​ | ​ | ​ | ​ | ​ | 4,456,145 | ​ | ​ | ​ | ​ | ​ | ​ | 828,795 | ​ | ​ | ​ | ​ | ​ | ​ | 1,868,289 | ​ | ​ | ​ | ​ | ​ | ​ | 56,706 | ​ | ​ | ​
​ | ​ | Add: The amount of change in fair values as of the vesting date (from end of the prior year) of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | (17,073) | ​ | ​ | ​ | ​ | ​ | ​ | (89,499) | ​ | ​ | ​ | ​ | ​ | ​ | 2,879,634 | ​ | ​ | ​ | ​ | ​ | ​ | 89,435 | ​ | ​ | ​ | ​ | ​ | ​ | (165,785) | ​ | ​ | ​ | ​ | ​ | ​ | (32,272) | ​ | ​ | ​
​ | ​ | Compensation Actually Paid | ​ | ​ | ​ | ​ | ​ | 894,752 | ​ | ​ | ​ | ​ | ​ | ​ | 409,560 | ​ | ​ | ​ | ​ | ​ | ​ | 13,102,240 | ​ | ​ | ​ | ​ | ​ | ​ | 2,755,988 | ​ | ​ | ​ | ​ | ​ | ​ | 5,331,974 | ​ | ​ | ​ | ​ | ​ | ​ | 1,483,327 | ​ | ​ | ​
​ (a) Each NEO received time-based restricted stock awards in each of the periods presented. The fair value of time-based restricted stock awards is dependent on the Company’s stock price. The Company’s closing stock price as of the dates listed are as follows: ​
​ | ​ | Date | ​ | ​ | ​ | Stock Price | ​ | ​
​ | ​ | 12/31/2019 | ​ | ​ | ​ | ​ | $ | 14.69 | ​ | ​ | ​
​ | ​ | 12/31/2020 | ​ | ​ | ​ | ​ | $ | 17.36 | ​ | ​ | ​
​ | ​ | 12/31/2021 | ​ | ​ | ​ | ​ | $ | 28.47 | ​ | ​ | ​
​ | ​ | 12/31/2022 | ​ | ​ | ​ | ​ | $ | 18.58 | ​ | ​ | ​
(b) Our NEOs received PRSUs during each of the periods presented, that are subject to the achievement of designated performance criteria, based on three-year total shareholder return. These PRSUs are valued based upon the Monte Carlo simulation method. Please see below for the per share fair value as of each respective date: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Per Share Fair Value at… | ​ | ​ | ​
​ | ​ | ​ | ​ | Award | ​ | ​ | ​ | Grant Date | ​ | ​ | ​ | Grant Date | ​ | ​ | ​ | 12/31/2019 | ​ | ​ | ​ | 12/31/2020 | ​ | ​ | ​ | 12/31/2021 | ​ | ​ | ​ | 12/31/2022 | ​ | ​ | ​
​ | ​ | ​ | 2018PRSU(c) | ​ | ​ | ​ | ​ | ​ | ​ | 10/1/2018 | ​ | ​ | ​ | ​ | ​ | $ | 15.58 | ​ | ​ | ​ | ​ | ​ | $ | 25.01 | ​ | ​ | ​ | ​ | ​ | $ | 31.99 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2019PRSU(d) | ​ | ​ | ​ | ​ | ​ | ​ | 3/14/2019 | ​ | ​ | ​ | ​ | ​ | $ | 14.46 | ​ | ​ | ​ | ​ | ​ | $ | 20.36 | ​ | ​ | ​ | ​ | ​ | $ | 24.81 | ​ | ​ | ​ | ​ | ​ | $ | 56.29 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2020PRSU(d) | ​ | ​ | ​ | ​ | ​ | ​ | 3/17/2020 | ​ | ​ | ​ | ​ | ​ | $ | 10.59 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 18.92 | ​ | ​ | ​ | ​ | ​ | $ | 43.47 | ​ | ​ | ​ | ​ | ​ | $ | 29.82 | ​ | ​ | ​ | ​
​ | ​ | ​ | 2021PRSU(e) | ​ | ​ | ​ | ​ | ​ | ​ | 3/12/2021 | ​ | ​ | ​ | ​ | ​ | $ | 27.81 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 40.60 | ​ | ​ | ​ | ​ | ​ | $ | 24.76 | ​ | ​ | ​ | ​
​ | ​ | ​ | 2022PRSU(e) | ​ | ​ | ​ | ​ | ​ | ​ | 3/17/2022 | ​ | ​ | ​ | ​ | ​ | $ | 45.28 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 22.27 | ​ | ​ | ​ | ​
​ (c) Granted to Dr. Miller only. ​ (d) Granted to Drs. Miller, Devasahayam, and Porshnev, and Mr. Kiernan. ​ (e) Granted to Drs. Miller, Devasahayam, and Porshnev, Mr. Kiernan, and Ms. Wilkerson. ​ (4) The values disclosed in this TSR column represent the measurement period value of an investment of $100 in respective stock or index as of December 31, 2019, and then valued again on each of December 31, 2020, 2021, and 2022. |  |  |  |  |  |  |  |
Company Selected Measure Name | Adjusted Operating Income |  |  |  |  |  |  |  |
Named Executive Officers, Footnote [Text Block] | (1) The PEO (principal executive officer) for each year presented was identified as Dr. Miller, the Company’s CEO. ​ (2) The Non-PEO NEOs for each year presented were identified as Mr. Kiernan, Drs. Devasahayam and Porshnev, and Ms. Wilkerson. |  |  |  |  |  |  |  |
PEO Total Compensation Amount | $ 5,914,884 | $ 4,526,501 | $ 2,610,509 |  |  |  |  |  |
PEO Actually Paid Compensation Amount | $ 894,752 | 13,102,240 | 5,331,974 |  |  |  |  |  |
Adjustment To PEO Compensation, Footnote [Text Block] | (3) A reconciliation of Total Compensation per the Summary Compensation Table to Compensation Actually Paid is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | 2022 | ​ | ​ | ​ | 2021 | ​ | ​ | ​ | 2020 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​
​ | ​ | Total Compensation from SCT | ​ | ​ | ​ | ​ | ​ | 5,914,884 | ​ | ​ | ​ | ​ | ​ | ​ | 1,769,683 | ​ | ​ | ​ | ​ | ​ | ​ | 4,526,501 | ​ | ​ | ​ | ​ | ​ | ​ | 1,514,852 | ​ | ​ | ​ | ​ | ​ | ​ | 2,610,509 | ​ | ​ | ​ | ​ | ​ | ​ | 1,138,308 | ​ | ​ | ​
​ | ​ | Deduct: Amounts Reported Under “Stock Awards” and “Option Awards” columns in SCT | ​ | ​ | ​ | ​ | ​ | (4,741,020) | ​ | ​ | ​ | ​ | ​ | ​ | (1,135,870) | ​ | ​ | ​ | ​ | ​ | ​ | (3,122,580) | ​ | ​ | ​ | ​ | ​ | ​ | (813,172) | ​ | ​ | ​ | ​ | ​ | ​ | (1,121,618) | ​ | ​ | ​ | ​ | ​ | ​ | (460,253) | ​ | ​ | ​
​ | ​ | Add: Year-end value of equity awards granted in covered year that were outstanding and unvested as of the end of the covered fiscal year﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | 2,517,420 | ​ | ​ | ​ | ​ | ​ | ​ | 603,132 | ​ | ​ | ​ | ​ | ​ | ​ | 4,362,540 | ​ | ​ | ​ | ​ | ​ | ​ | 1,136,078 | ​ | ​ | ​ | ​ | ​ | ​ | 2,140,579 | ​ | ​ | ​ | ​ | ​ | ​ | 780,839 | ​ | ​ | ​
​ | ​ | Add: The amount of change in fair values as of year-end (from end of the prior year) of awards granted in prior years and outstanding at year-end﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | (2,779,460) | ​ | ​ | ​ | ​ | ​ | ​ | (737,886) | ​ | ​ | ​ | ​ | ​ | ​ | 4,456,145 | ​ | ​ | ​ | ​ | ​ | ​ | 828,795 | ​ | ​ | ​ | ​ | ​ | ​ | 1,868,289 | ​ | ​ | ​ | ​ | ​ | ​ | 56,706 | ​ | ​ | ​
​ | ​ | Add: The amount of change in fair values as of the vesting date (from end of the prior year) of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | (17,073) | ​ | ​ | ​ | ​ | ​ | ​ | (89,499) | ​ | ​ | ​ | ​ | ​ | ​ | 2,879,634 | ​ | ​ | ​ | ​ | ​ | ​ | 89,435 | ​ | ​ | ​ | ​ | ​ | ​ | (165,785) | ​ | ​ | ​ | ​ | ​ | ​ | (32,272) | ​ | ​ | ​
​ | ​ | Compensation Actually Paid | ​ | ​ | ​ | ​ | ​ | 894,752 | ​ | ​ | ​ | ​ | ​ | ​ | 409,560 | ​ | ​ | ​ | ​ | ​ | ​ | 13,102,240 | ​ | ​ | ​ | ​ | ​ | ​ | 2,755,988 | ​ | ​ | ​ | ​ | ​ | ​ | 5,331,974 | ​ | ​ | ​ | ​ | ​ | ​ | 1,483,327 | ​ | ​ | ​
​ (a) Each NEO received time-based restricted stock awards in each of the periods presented. The fair value of time-based restricted stock awards is dependent on the Company’s stock price. The Company’s closing stock price as of the dates listed are as follows: ​
​ | ​ | Date | ​ | ​ | ​ | Stock Price | ​ | ​
​ | ​ | 12/31/2019 | ​ | ​ | ​ | ​ | $ | 14.69 | ​ | ​ | ​
​ | ​ | 12/31/2020 | ​ | ​ | ​ | ​ | $ | 17.36 | ​ | ​ | ​
​ | ​ | 12/31/2021 | ​ | ​ | ​ | ​ | $ | 28.47 | ​ | ​ | ​
​ | ​ | 12/31/2022 | ​ | ​ | ​ | ​ | $ | 18.58 | ​ | ​ | ​
(b) Our NEOs received PRSUs during each of the periods presented, that are subject to the achievement of designated performance criteria, based on three-year total shareholder return. These PRSUs are valued based upon the Monte Carlo simulation method. Please see below for the per share fair value as of each respective date: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Per Share Fair Value at… | ​ | ​ | ​
​ | ​ | ​ | ​ | Award | ​ | ​ | ​ | Grant Date | ​ | ​ | ​ | Grant Date | ​ | ​ | ​ | 12/31/2019 | ​ | ​ | ​ | 12/31/2020 | ​ | ​ | ​ | 12/31/2021 | ​ | ​ | ​ | 12/31/2022 | ​ | ​ | ​
​ | ​ | ​ | 2018PRSU(c) | ​ | ​ | ​ | ​ | ​ | ​ | 10/1/2018 | ​ | ​ | ​ | ​ | ​ | $ | 15.58 | ​ | ​ | ​ | ​ | ​ | $ | 25.01 | ​ | ​ | ​ | ​ | ​ | $ | 31.99 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2019PRSU(d) | ​ | ​ | ​ | ​ | ​ | ​ | 3/14/2019 | ​ | ​ | ​ | ​ | ​ | $ | 14.46 | ​ | ​ | ​ | ​ | ​ | $ | 20.36 | ​ | ​ | ​ | ​ | ​ | $ | 24.81 | ​ | ​ | ​ | ​ | ​ | $ | 56.29 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2020PRSU(d) | ​ | ​ | ​ | ​ | ​ | ​ | 3/17/2020 | ​ | ​ | ​ | ​ | ​ | $ | 10.59 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 18.92 | ​ | ​ | ​ | ​ | ​ | $ | 43.47 | ​ | ​ | ​ | ​ | ​ | $ | 29.82 | ​ | ​ | ​ | ​
​ | ​ | ​ | 2021PRSU(e) | ​ | ​ | ​ | ​ | ​ | ​ | 3/12/2021 | ​ | ​ | ​ | ​ | ​ | $ | 27.81 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 40.60 | ​ | ​ | ​ | ​ | ​ | $ | 24.76 | ​ | ​ | ​ | ​
​ | ​ | ​ | 2022PRSU(e) | ​ | ​ | ​ | ​ | ​ | ​ | 3/17/2022 | ​ | ​ | ​ | ​ | ​ | $ | 45.28 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 22.27 | ​ | ​ | ​ | ​
​ (c) Granted to Dr. Miller only. ​ (d) Granted to Drs. Miller, Devasahayam, and Porshnev, and Mr. Kiernan. ​ (e) Granted to Drs. Miller, Devasahayam, and Porshnev, Mr. Kiernan, and Ms. Wilkerson. |  |  |  |  |  |  |  |
Non-PEO NEO Average Total Compensation Amount | $ 1,769,683 | 1,514,852 | 1,138,308 |  |  |  |  |  |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 409,560 | 2,755,988 | 1,483,327 |  |  |  |  |  |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (3) A reconciliation of Total Compensation per the Summary Compensation Table to Compensation Actually Paid is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | 2022 | ​ | ​ | ​ | 2021 | ​ | ​ | ​ | 2020 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​ | ​ | PEO ($) | ​ | ​ | ​ | Average for Non-PEO NEOs ($) | ​ | ​
​ | ​ | Total Compensation from SCT | ​ | ​ | ​ | ​ | ​ | 5,914,884 | ​ | ​ | ​ | ​ | ​ | ​ | 1,769,683 | ​ | ​ | ​ | ​ | ​ | ​ | 4,526,501 | ​ | ​ | ​ | ​ | ​ | ​ | 1,514,852 | ​ | ​ | ​ | ​ | ​ | ​ | 2,610,509 | ​ | ​ | ​ | ​ | ​ | ​ | 1,138,308 | ​ | ​ | ​
​ | ​ | Deduct: Amounts Reported Under “Stock Awards” and “Option Awards” columns in SCT | ​ | ​ | ​ | ​ | ​ | (4,741,020) | ​ | ​ | ​ | ​ | ​ | ​ | (1,135,870) | ​ | ​ | ​ | ​ | ​ | ​ | (3,122,580) | ​ | ​ | ​ | ​ | ​ | ​ | (813,172) | ​ | ​ | ​ | ​ | ​ | ​ | (1,121,618) | ​ | ​ | ​ | ​ | ​ | ​ | (460,253) | ​ | ​ | ​
​ | ​ | Add: Year-end value of equity awards granted in covered year that were outstanding and unvested as of the end of the covered fiscal year﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | 2,517,420 | ​ | ​ | ​ | ​ | ​ | ​ | 603,132 | ​ | ​ | ​ | ​ | ​ | ​ | 4,362,540 | ​ | ​ | ​ | ​ | ​ | ​ | 1,136,078 | ​ | ​ | ​ | ​ | ​ | ​ | 2,140,579 | ​ | ​ | ​ | ​ | ​ | ​ | 780,839 | ​ | ​ | ​
​ | ​ | Add: The amount of change in fair values as of year-end (from end of the prior year) of awards granted in prior years and outstanding at year-end﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | (2,779,460) | ​ | ​ | ​ | ​ | ​ | ​ | (737,886) | ​ | ​ | ​ | ​ | ​ | ​ | 4,456,145 | ​ | ​ | ​ | ​ | ​ | ​ | 828,795 | ​ | ​ | ​ | ​ | ​ | ​ | 1,868,289 | ​ | ​ | ​ | ​ | ​ | ​ | 56,706 | ​ | ​ | ​
​ | ​ | Add: The amount of change in fair values as of the vesting date (from end of the prior year) of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year﻿(a)(b) | ​ | ​ | ​ | ​ | ​ | (17,073) | ​ | ​ | ​ | ​ | ​ | ​ | (89,499) | ​ | ​ | ​ | ​ | ​ | ​ | 2,879,634 | ​ | ​ | ​ | ​ | ​ | ​ | 89,435 | ​ | ​ | ​ | ​ | ​ | ​ | (165,785) | ​ | ​ | ​ | ​ | ​ | ​ | (32,272) | ​ | ​ | ​
​ | ​ | Compensation Actually Paid | ​ | ​ | ​ | ​ | ​ | 894,752 | ​ | ​ | ​ | ​ | ​ | ​ | 409,560 | ​ | ​ | ​ | ​ | ​ | ​ | 13,102,240 | ​ | ​ | ​ | ​ | ​ | ​ | 2,755,988 | ​ | ​ | ​ | ​ | ​ | ​ | 5,331,974 | ​ | ​ | ​ | ​ | ​ | ​ | 1,483,327 | ​ | ​ | ​
​ (a) Each NEO received time-based restricted stock awards in each of the periods presented. The fair value of time-based restricted stock awards is dependent on the Company’s stock price. The Company’s closing stock price as of the dates listed are as follows: ​
​ | ​ | Date | ​ | ​ | ​ | Stock Price | ​ | ​
​ | ​ | 12/31/2019 | ​ | ​ | ​ | ​ | $ | 14.69 | ​ | ​ | ​
​ | ​ | 12/31/2020 | ​ | ​ | ​ | ​ | $ | 17.36 | ​ | ​ | ​
​ | ​ | 12/31/2021 | ​ | ​ | ​ | ​ | $ | 28.47 | ​ | ​ | ​
​ | ​ | 12/31/2022 | ​ | ​ | ​ | ​ | $ | 18.58 | ​ | ​ | ​
(b) Our NEOs received PRSUs during each of the periods presented, that are subject to the achievement of designated performance criteria, based on three-year total shareholder return. These PRSUs are valued based upon the Monte Carlo simulation method. Please see below for the per share fair value as of each respective date: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Per Share Fair Value at… | ​ | ​ | ​
​ | ​ | ​ | ​ | Award | ​ | ​ | ​ | Grant Date | ​ | ​ | ​ | Grant Date | ​ | ​ | ​ | 12/31/2019 | ​ | ​ | ​ | 12/31/2020 | ​ | ​ | ​ | 12/31/2021 | ​ | ​ | ​ | 12/31/2022 | ​ | ​ | ​
​ | ​ | ​ | 2018PRSU(c) | ​ | ​ | ​ | ​ | ​ | ​ | 10/1/2018 | ​ | ​ | ​ | ​ | ​ | $ | 15.58 | ​ | ​ | ​ | ​ | ​ | $ | 25.01 | ​ | ​ | ​ | ​ | ​ | $ | 31.99 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2019PRSU(d) | ​ | ​ | ​ | ​ | ​ | ​ | 3/14/2019 | ​ | ​ | ​ | ​ | ​ | $ | 14.46 | ​ | ​ | ​ | ​ | ​ | $ | 20.36 | ​ | ​ | ​ | ​ | ​ | $ | 24.81 | ​ | ​ | ​ | ​ | ​ | $ | 56.29 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | 2020PRSU(d) | ​ | ​ | ​ | ​ | ​ | ​ | 3/17/2020 | ​ | ​ | ​ | ​ | ​ | $ | 10.59 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 18.92 | ​ | ​ | ​ | ​ | ​ | $ | 43.47 | ​ | ​ | ​ | ​ | ​ | $ | 29.82 | ​ | ​ | ​ | ​
​ | ​ | ​ | 2021PRSU(e) | ​ | ​ | ​ | ​ | ​ | ​ | 3/12/2021 | ​ | ​ | ​ | ​ | ​ | $ | 27.81 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 40.60 | ​ | ​ | ​ | ​ | ​ | $ | 24.76 | ​ | ​ | ​ | ​
​ | ​ | ​ | 2022PRSU(e) | ​ | ​ | ​ | ​ | ​ | ​ | 3/17/2022 | ​ | ​ | ​ | ​ | ​ | $ | 45.28 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | $ | 22.27 | ​ | ​ | ​ | ​
​ (c) Granted to Dr. Miller only. ​ (d) Granted to Drs. Miller, Devasahayam, and Porshnev, and Mr. Kiernan. ​ (e) Granted to Drs. Miller, Devasahayam, and Porshnev, Mr. Kiernan, and Ms. Wilkerson. |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | The graph below reflects the relationships between the PEO and Average Non-PEO NEO Compensation Actually Paid (“CAP”), and the Company’s cumulative indexed Total Shareholder Return, or TSR (assuming an initial fixed investment of $100), and our Peer Group TSR (assuming an initial fixed investment of $100), for the fiscal years ended December 31, 2020, 2021, and 2022: |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure [Text Block] | The graph below reflects the relationships between the PEO and Average Non-PEO NEO Compensation Actually Paid (“CAP”) and the Company’s reported GAAP Net Income and Adjusted Operating Income for the fiscal years ended December 31, 2020, 2021, and 2022: |  |  |  |  |  |  |  |
Tabular List [Table Text Block] | The Company’s most important performance measures for each of the PEO and non-PEO NEOs is discussed under the 2022 Management Bonus Plan (the “2022 Plan”) subsection of the Compensation Discussion and Analysis section of this proxy. As more fully described in this subsection, the 2022 Plan was based on the financial performance of the Company as measured by Adjusted Operating Income. This financial metric was selected because it closely aligns operating performance with earnings per share, a key driver of shareholder value. Under the 2022 Plan, 25% of each participant’s bonus was based on individual performance which, for each of the PEO and non-PEO NEOs, factored financial goals incorporating revenue, gross margin, bookings and expenses. |  |  |  |  |  |  |  |
Total Shareholder Return Amount | $ 126.48 | 193.81 | 118.18 |  |  |  |  |  |
Peer Group Total Shareholder Return Amount | 36.09 | 81.82 | 132.76 |  |  |  |  |  |
Net Income (Loss) | $ 166,942,000 | $ 26,038,000 | $ (8,391,000) |  |  |  |  |  |
Company Selected Measure Amount | 116,600 | 104,300 | 66,900 |  |  |  |  |  |
PEO Name | Dr. Miller | Dr. Miller | Dr. Miller |  |  |  |  |  |
Share Price | $ / shares | $ 18.58 | $ 28.47 | $ 17.36 |  |  |  | $ 14.69 |  |
Grand Date Value of Performance-Based Restricted Stock Units, Grant Date 10/1/2018 | $ / shares |  |  |  |  |  |  |  |  | $ 15.58
Fair Value of Performance-Based Restricted Stock Units, Grant Date 10/1/2018 | $ / shares |  |  | 31.99 |  |  |  | 25.01 |  |
Grand Date Value of Performance-Based Restricted Stock Units, Grant Date 3/14/2019 | $ / shares |  |  |  |  |  |  |  | $ 14.46 |
Fair Value of Performance-Based Restricted Stock Units, Grant Date 3/14/2019 | $ / shares |  | 56.29 | 24.81 |  |  |  | $ 20.36 |  |
Grand Date Value of Performance-Based Restricted Stock Units, Grant Date 3/17/2020 | $ / shares |  |  |  |  |  | $ 10.59 |  |  |
Fair Value of Performance-Based Restricted Stock Units, Grant Date 3/17/2020 | $ / shares | 29.82 | 43.47 | $ 18.92 |  |  |  |  |  |
Grand Date Value of Performance-Based Restricted Stock Units, Grant Date 3/12/2021 | $ / shares |  |  |  |  | $ 27.81 |  |  |  |
Fair Value of Performance-Based Restricted Stock Units, Grant Date 3/12/2021 | $ / shares | 24.76 | $ 40.6 |  |  |  |  |  |  |
Grand Date Value of Performance-Based Restricted Stock Units, Grant Date 3/17/2022 | $ / shares |  |  |  | $ 45.28 |  |  |  |  |
Fair Value of Performance-Based Restricted Stock Units, Grant Date 3/17/2022 | $ / shares | $ 22.27 |  |  |  |  |  |  |  |
Measure [Axis]: 1 |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Measure Name | Adjusted Operating Income |  |  |  |  |  |  |  |
PEO [Member] | Equity Awards Adjustments, Amounts Reported Under Stock Awards and Option Awards Columns in SCT [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | $ (4,741,020) | $ (3,122,580) | $ (1,121,618) |  |  |  |  |  |
PEO [Member] | Equity Awards Adjustments, Year-end Value of Equity Awards Granted in Covered Year hat Were Outstanding and Unvested as of the End of the Covered Fiscal Year﻿ [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 2,517,420 | 4,362,540 | 2,140,579 |  |  |  |  |  |
PEO [Member] | Equity Awards Adjustments, Change in Fair Values as of Year-end (from End of the Prior year) of Awards Granted in Prior Years and Outstanding at Year-end [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (2,779,460) | 4,456,145 | 1,868,289 |  |  |  |  |  |
PEO [Member] | Equity Awards Adjustments, Change in Fair Values as of the Vesting Date (from End of the Prior Year) of Awards Granted in Any Prior Fiscal Year for Which Vesting Conditions were Satisfied During the Covered Fiscal Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (17,073) | 2,879,634 | (165,785) |  |  |  |  |  |
Non-PEO NEO [Member] | Equity Awards Adjustments, Amounts Reported Under Stock Awards and Option Awards Columns in SCT [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (1,135,870) | (813,172) | (460,253) |  |  |  |  |  |
Non-PEO NEO [Member] | Equity Awards Adjustments, Year-end Value of Equity Awards Granted in Covered Year hat Were Outstanding and Unvested as of the End of the Covered Fiscal Year﻿ [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 603,132 | 1,136,078 | 780,839 |  |  |  |  |  |
Non-PEO NEO [Member] | Equity Awards Adjustments, Change in Fair Values as of Year-end (from End of the Prior year) of Awards Granted in Prior Years and Outstanding at Year-end [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (737,886) | 828,795 | 56,706 |  |  |  |  |  |
Non-PEO NEO [Member] | Equity Awards Adjustments, Change in Fair Values as of the Vesting Date (from End of the Prior Year) of Awards Granted in Any Prior Fiscal Year for Which Vesting Conditions were Satisfied During the Covered Fiscal Year [Member] |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | $ (89,499) | $ 89,435 | $ (32,272) |  |  |  |  |  |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580 Reference 25: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_FairValueOfPerformanceBasedRestrictedStockUnitsGrantDate1012018
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_FairValueOfPerformanceBasedRestrictedStockUnitsGrantDate3122021
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_FairValueOfPerformanceBasedRestrictedStockUnitsGrantDate3142019
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_FairValueOfPerformanceBasedRestrictedStockUnitsGrantDate3172020
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_FairValueOfPerformanceBasedRestrictedStockUnitsGrantDate3172022
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_GrandDateValueOfPerformanceBasedRestrictedStockUnitsGrantDate1012018
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_GrandDateValueOfPerformanceBasedRestrictedStockUnitsGrantDate3122021
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_GrandDateValueOfPerformanceBasedRestrictedStockUnitsGrantDate3142019
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_GrandDateValueOfPerformanceBasedRestrictedStockUnitsGrantDate3172020
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | veco_GrandDateValueOfPerformanceBasedRestrictedStockUnitsGrantDate3172022
Namespace Prefix: | veco_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=veco_EquityAwardsAdjustmentsAmountsReportedUnderStockAwardsAndOptionAwardsColumnsInSCTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=veco_EquityAwardsAdjustmentsYearendValueOfEquityAwardsGrantedInCoveredYearHatWereOutstandingAndUnvestedAsOfTheEndOfTheCoveredFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=veco_EquityAwardsAdjustmentsChangeInFairValuesAsOfYearendfromEndOfThePriorYearOfAwardsGrantedInPriorYearsAndOutstandingAtYearendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=veco_EquityAwardsAdjustmentsChangeInFairValuesAsOfTheVestingDatefromEndOfThePriorYearOfAwardsGrantedInAnyPriorFiscalYearForWhichVestingConditionsWereSatisfiedDuringTheCoveredFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |